Pharming Group N.V. (PHAR) Q3 2026 earnings review
Pharming sales jump 21%, but its outlook implies Q4 shrinks
Pharming's rare-disease pill Joenja expanded into new countries, while restocking at a US pharmacy lifted its older drug RUCONEST. Total sales at the Dutch biotech company rose 21% to $118 million, and operating profit nearly doubled on lower overhead costs. Interim co-chief executive Kenneth Lynard narrowed the full-year sales range around the same middle point, which by our math leaves fourth-quarter revenue down 2% from a year ago.
| Total revenue | $117.6M +21% from a year ago |
|---|---|
| Joenja revenue | $23.8M +58% from a year ago |
| Operating profit | $29.9M +89% from a year ago |
| Full-year revenue outlook | Unchanged middle of the range: $385M (+2.4% growth) |
⚖️ Verdict: 🟢 Bullish
The story got better because Joenja won early US approval for children, launched in Germany and Japan, and showed positive early trial data in a larger immune disorder. Overhead cost cuts also lifted cash generation, easing balance sheet pressure. One caution: beating the second-half sales pace did not prompt a raise to the full-year midpoint, because early pharmacy buying pulled RUCONEST orders into the third quarter and another inventory write-down hit gross margin.
The question now is whether leniolisib works in the broader common variable immunodeficiency population without a specific genetic link, and whether RUCONEST demand holds up once pharmacy restocking fades. If the trial succeeds and RUCONEST steadies, Pharming can fund a much larger commercial opportunity; if either falls short, growth will rely on small APDS patient additions. November's Phase II readout and fourth-quarter RUCONEST sales will decide both.
🐂 Bull Case
Joenja Launches and Pediatric Approval Expand the Franchise
Joenja, Pharming's pill for a rare immune disorder called APDS, is growing into an international franchise. Third-quarter revenue rose 58% from a year ago to $23.8 million, as launches in Germany and Japan joined steady patient additions in the United States and the United Kingdom.
- US Joenja revenue: $15.9 million, up 19% from a year ago
- International Joenja revenue: $7.9 million, up from $1.7 million a year ago
- International paid patients: 75 at quarter end, including 30 in launch markets
- Global diagnosed APDS patients identified: 1,056, up from 1,042 last quarter
The US Food and Drug Administration also cleared 40 mg and 50 mg doses for children aged 4 to 11 weighing at least 27 kg on September 11, six weeks ahead of schedule. Because shipments started in October, the third quarter did not include this pediatric boost. Meanwhile, international sales received a boost from what the company called a "temporary benefit from ordering patterns in other international markets".
What to watch: US paid patient additions in the fourth quarter, and the January 30, 2027 regulatory decision on lower doses for smaller children. A jump in US patients above the recent pace of four to seven per quarter would show that children are switching onto paid therapy.
Lower Marketing and Admin Costs Doubled Operating Profit
Pharming's cost cuts from last October are lifting profitability even as the biotech group spends more on clinical trials. Operating profit rose 89% from a year ago to $29.9 million, and operating profit excluding one-offs more than doubled to $35.0 million from $16.0 million.
Two overhead lines drove the improvement. Marketing and sales costs fell by 10.0 percentage points of revenue to 25.1%, while general and administrative overhead dropped 4.2 percentage points to 13.3%. Those savings more than covered research and development, which rose 1.1 percentage points to 25.2% of revenue. Operating cash flow reached $32.4 million, lifting total cash to $190.9 million and easing concerns around the $99.9 million in convertible bonds.
What to watch: fourth-quarter operating expenses, which the updated full-year outlook puts at $88.5 million to $93.5 million by our math. Staying inside that range would confirm the company can fund its late-stage trials without eroding cash.
Early Clinical Data Supports Leniolisib Beyond APDS
Pharming wants to prove that leniolisib, the active drug in Joenja, can treat immune disorders affecting far more people than APDS. Interim co-chief executive Leverne Marsh said: "Together, results from both trials will inform the path toward a potential registrational study in the broader and larger CVID population."
In October, the Dutch company reported positive Phase II results in 13 patients with genetically linked immune deficiencies, nine of whom also had common variable immunodeficiency (CVID). Spleen volume shrank by an average of 26.4%, and all 12 patients who finished the study chose to stay on the drug in a three-year extension. Because CVID affects about 39 people per million versus 1.5 per million for APDS, success here would multiply the drug's market.
What to watch: topline data in November 2026 from the second Phase II study in broader CVID patients without a required genetic link. Strong spleen reduction and clean safety in that larger group are needed to justify a single Phase III trial.
🐻 Bear Case
Pharmacy Restocking Drove RUCONEST, While Q4 Outlook Shrinks
Interim co-chief executive Kenneth Lynard said RUCONEST, an injectable treatment for hereditary swelling attacks, grew 14% to $93.8 million, "supported by stabilized U.S. demand with the strongest retention in the high-burden patient segment, and continued new patient and prescribers additions". However, the release notes that the jump also reflected an "early seasonal increase in channel inventory at a single U.S. specialty pharmacy customer following significant drawdowns earlier in the year".
Patient metrics and the full-year plan show that oral rivals still pressure the franchise. The active patient base slipped to "over 90%" of year-ago levels from 93% in the second quarter, and the company did not report exact new patient enrollments after disclosing 84 last quarter. Furthermore, keeping the full-year revenue midpoint at $385.0 million after a $20.3 million third-quarter increase leaves $104.8 million for the fourth quarter by our math, down 1.6% from a year ago.
What to watch: fourth-quarter RUCONEST revenue against last year's $86.7 million. A drop in the fourth quarter would confirm that third-quarter pharmacy restocking pulled sales forward rather than marking a true demand rebound.
Second Inventory Write-Down Cuts Gross Margin
Pharming had aimed to resolve its manufacturing inventory issues before the end of the third quarter, after writing off $4.9 million of unusable material in the second quarter. Instead, the biotech group recorded another $5.1 million in "manufacturing-related impairments of inventory" during the third quarter, bringing the nine-month total to $10.0 million.
Because of the charge, the cost of making products rose by 5.8 percentage points of revenue to 13.1%, pushing gross margin down from 92.7% a year ago to 86.9%. Excluding the $5.1 million write-down, gross margin would have been 91.2% by our math, showing that underlying pricing remains intact while production quality problems persist.
What to watch: cost of sales in the fourth quarter. Any further inventory write-down would indicate that the contract manufacturing problem remains unresolved entering 2027.
👓 Other Themes
CEO Steps Down and FALCON Trial Enrollment Slips
Chief executive Fabrice Chouraqui stepped down on September 29 by mutual agreement, and the board named commercial chief Leverne Marsh and finance chief Kenneth Lynard as interim co-chief executives. Separately, Pharming pushed back enrollment completion for FALCON, its pivotal trial of napazimone in mitochondrial disease, from late 2026 to the first half of 2027, pushing top-line data into 2028.
Currency Gains Lifted Net Profit
Favorable exchange rate movements between the euro and the US dollar generated a $2.6 million foreign currency gain in the third quarter, compared with a $0.4 million loss a year ago. That swing turned net finance results from a $3.1 million expense into a $1.4 million gain, helping net profit triple from $7.5 million to $22.4 million.
💲 Other KPIs
Uncollected customer bills rose 31.3% from last quarter and 71.6% from a year ago, outpacing the 30.4% quarterly jump in revenue. Management noted that higher receivables reduced operating cash flow, reflecting late-quarter specialty pharmacy restocking in the US and ordering patterns in international markets.
Paid patient numbers in the United States grew 17.2% from 116 a year ago and added 4 patients during the quarter, following additions of 7 in the first quarter and 5 in the second. The figure excludes newly approved doses for children aged 4 to 11, which began shipping in October.
Stock on the balance sheet fell 11.4% from $65.4 million last quarter and 10.7% from $64.9 million at the end of 2025. The reduction reflects both the $5.1 million manufacturing write-down in the third quarter and higher shipments to the US specialty pharmacy channel.
🔮 Guidance
Unchanged at the middle of the range. Pharming narrowed the band by $5 million on each side, keeping the midpoint at $385.0 million, or 2.4% growth for the year. By our math, that leaves $104.8 million for the fourth quarter, down 1.6% from $106.5 million a year ago and down 10.9% from the third quarter. The company previously cut this midpoint by $30 million in the second quarter.
Cut. The group lowered its full-year spending plan by $5 million, after a $15 million reduction last quarter, leaving expenses up 0.4% for the year at the midpoint. By our math, the outlook implies $91.0 million of operating costs in the fourth quarter, up 9.1% from a year ago and up 22.0% from the third quarter as trial spending steps up.
❓ Key Questions
How much did pharmacy restocking add to RUCONEST sales?
RUCONEST rose $21.5 million from last quarter, aided by early seasonal buying at one US specialty pharmacy, while the full-year outlook implies fourth-quarter revenue falls from the third quarter.
Why did manufacturing inventory write-downs continue in Q3?
Management previously expected to conclude its inventory review in the third quarter, yet booked another $5.1 million charge after the $4.9 million write-down in the second quarter.
How many new patients enrolled on RUCONEST in Q3?
Pharming disclosed 50 new enrollments in the first quarter and 84 in the second, but omitted the figure this quarter while the active patient base slipped from 93% to over 90% of year-ago levels.
Why did FALCON trial enrollment slip into 2027?
With over 50 sites active and 145 of 180 patients expected by year-end, completing the final 35 patients will now take into the first half of 2027, delaying topline results into 2028.